NCT00980174View on ClinicalTrials.gov

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

PHASE3CompletedINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

June 21, 2011

Study Completion Date

May 23, 2012

Conditions

Low Bone MassLow Bone Mineral DensityMales With OsteoporosisOsteopeniaOsteoporosis

Interventions

DRUG

60 mg denosumab

60 mg denosumab (SC injection every 6 months)

OTHER

Placebo

Placebo for denosumab (SC injection every 6 months)

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY